Mirtazapine Aurobindo (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine and serotonin. It also antagonizes postsynaptic 5‑HT2 and 5‑HT3 receptors and strongly blocks histamine H1 receptors, enhancing monoaminergic neurotransmission while providing sedative effects.

The appropriate dose of mirtazapine is determined by the prescribing clinician based on the individual patient's clinical condition, response, and tolerability. Dosage adjustments are made according to professional guidelines and patient-specific factors; patients should follow the prescriber’s instructions.

Safety data for mirtazapine in pregnancy and lactation are limited, and the medication is generally classified as contraindicated unless the potential benefit outweighs the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives and risks with their healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, whereas SSRIs primarily inhibit serotonin reuptake. Mirtazapine often causes sedation and weight gain, which can be advantageous for patients with insomnia or poor appetite, while SSRIs are generally activating and have a different side‑effect profile. Choice depends on individual patient needs and tolerability.

Mirtazapine Aurobindo should be stored at ambient temperature, below 25 °C, in the original packaging. Protect the product from moisture, direct sunlight, and excessive heat to maintain its stability and potency throughout its shelf life.

Mirtazapine Aurobindo is taken orally, usually once daily in the evening to take advantage of its sedative effect. The tablet should be swallowed whole with water and not chewed or crushed unless otherwise directed by a healthcare professional.

Serious risks include the rare occurrence of agranulocytosis or severe neutropenia, seizures, severe hypersensitivity reactions such as Stevens‑Johnson syndrome, and the emergence or worsening of suicidal thoughts, particularly during the initial weeks of therapy.

Mirtazapine should be avoided in patients who are currently taking monoamine oxidase inhibitors, have a known hypersensitivity to the drug, or have uncontrolled severe medical conditions that could be aggravated by its sedative or metabolic effects. A thorough medical review is required before initiation.